These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 32317280

  • 21. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS, Harder BG, Roos A, Peng S, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.
    Neuro Oncol; 2018 Sep 03; 20(10):1321-1330. PubMed ID: 29897522
    [Abstract] [Full Text] [Related]

  • 22. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
    Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang S, Hong B, Wang Q, Ju J, Cheng C, Li C, Wan C, Wang Y, Zhou J, Kang C.
    Theranostics; 2024 Sep 03; 14(7):2835-2855. PubMed ID: 38773970
    [Abstract] [Full Text] [Related]

  • 23. Interplay of m6 A and histone modifications contributes to temozolomide resistance in glioblastoma.
    Li F, Chen S, Yu J, Gao Z, Sun Z, Yi Y, Long T, Zhang C, Li Y, Pan Y, Qin C, Long W, Liu Q, Zhao W.
    Clin Transl Med; 2021 Sep 03; 11(9):e553. PubMed ID: 34586728
    [Abstract] [Full Text] [Related]

  • 24. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J, Gao G, Wei X, Wang Y.
    BMC Cancer; 2022 Jul 18; 22(1):786. PubMed ID: 35850753
    [Abstract] [Full Text] [Related]

  • 25. Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment.
    Lustig SD, Kodali SK, Longo SL, Kundu S, Viapiano MS.
    Anticancer Res; 2022 Feb 18; 42(2):723-730. PubMed ID: 35093870
    [Abstract] [Full Text] [Related]

  • 26. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F, Augello FR, Artone S, Gugu MK, Cifone MG, Cinque B, Palumbo P.
    Int J Mol Sci; 2022 Jan 28; 23(3):. PubMed ID: 35163465
    [Abstract] [Full Text] [Related]

  • 27. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.
    Neuro Oncol; 2017 Feb 01; 19(2):186-196. PubMed ID: 27370399
    [Abstract] [Full Text] [Related]

  • 28. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L, Tang S, Yu Y, Lv Y, Wang A, Yan X, Li N, Sha C, Sun K, Li Y.
    Mol Pharm; 2021 Mar 01; 18(3):915-927. PubMed ID: 33417456
    [Abstract] [Full Text] [Related]

  • 29. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L, Li Z, Hu S, Deng Q, Hao P, Guo S.
    Cancer Chemother Pharmacol; 2022 Feb 01; 89(2):217-229. PubMed ID: 35039898
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, He J, Wang F, Li P, Ge XS, Li FC.
    Oncotarget; 2017 Apr 04; 8(14):22783-22799. PubMed ID: 28187000
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J, Zeng A, Zhang Z, Shi Z, Yan W, You Y.
    EBioMedicine; 2019 Apr 04; 42():238-251. PubMed ID: 30917935
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
    Li XD, Wang MJ, Zheng JL, Wu YH, Wang X, Jiang XB.
    Cancer Sci; 2021 Nov 04; 112(11):4543-4552. PubMed ID: 34390075
    [Abstract] [Full Text] [Related]

  • 40. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
    Ma Z, Cai S, Xiong Q, Liu W, Xia H, Zhu Z, Huang Z, Yan X, Wang Q.
    Apoptosis; 2022 Feb 04; 27(1-2):80-89. PubMed ID: 35037107
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.